Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis

Author(s): Wen Xu, Bei Wang, Yuxuan Cai, Chong Guo, Kai Liu and Chengfu Yuan*

Volume 27, Issue 20, 2021

Published on: 26 October, 2020

Page: [2337 - 2343] Pages: 7

DOI: 10.2174/1381612826666201026150857

Price: $65

Abstract

Background: Long non-coding RNA (lncRNA) with little or no coding ability has shown a variety of biological functions in cancer, including epigenetic regulation, DNA damage, regulation of microRNAs, and participation in signal transduction pathways. LncRNA can be used as an oncogene and tumor suppressor gene through transcriptional regulation in cancer. For example, the over-expressed lncRNA DLEU2 promotes the occurrence of laryngeal cancer, lung cancer, hepatocellular carcinoma, etc., and inhibits the progression of chronic lymphocytic leukemia. Deleted in Lymphocytic Leukemia 2 (DLEU2), as one of the long non-coding RNAs, was first found in chronic lymphoblastic leukemia and drawn into the progress of innumerable cancers. The molecular mechanism of DLEU2 in multiple tumors will be revealed.

Methods: In this review, current studies on the biological functions and mechanisms of DLEU2 in tumors are summarized and analyzed; related researches are systematically retrieved and collected through PubMed.

Results: DLEU2, a novel cancer-related lncRNA, has been demonstrated to be abnormally expressed in various malignant tumors, including leukemia, esophageal cancer, lung cancer, glioma, hepatocellular carcinoma, malignant pleural mesothelioma, bladder cancer, pancreatic cancer, pharynx and throat cancer, renal clear cell carcinoma, breast cancer, osteosarcoma. Besides, lncRNA DLEU2 has been shown to be involved in the process of proliferation, migration, invasion and inhibition of apoptosis of cancer cells.

Conclusion: Due to the biological functions and mechanisms involved in DLEU2, it may represent an available biomarker or potential therapeutic target in a variety of malignant tumors.

Keywords: Long non-coding RNA, DLEU2, tumorigenesis, biomarker, potential therapeutic target, epigenetic regulation.

« Previous Next »
[1]
Bergmann JH, Spector DL. Long non-coding RNAs: modulators of nuclear structure and function. Curr Opin Cell Biol 2014; 26: 10-8.
[http://dx.doi.org/10.1016/j.ceb.2013.08.005] [PMID: 24529241]
[2]
Nava-Rodríguez MP, Domínguez-Cruz MD, Aguilar-López LB, Borjas-Gutiérrez C, Magaña-Torres MT, González-García JR. Genomic instability in a chronic lymphocytic leukemia patient with mono-allelic deletion of the DLEU and RB1 genes. Mol Cytogenet 2019; 12: 2.
[http://dx.doi.org/10.1186/s13039-019-0417-5] [PMID: 30733830]
[3]
Lu T, Wang R, Cai H, Cui Y. Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020.
[4]
Zhou Y, Shi H, Du Y, et al. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis. Aging (Albany NY) 2019; 11(18): 7386-401.
[http://dx.doi.org/10.18632/aging.102226] [PMID: 31541993]
[5]
Xie Z, Li X, Chen H, Zeng A, Shi Y, Tang Y. The lncRNA-DLEU2/miR-186-5p/PDK3 axis promotes the progress of glioma cells. Am J Transl Res 2019; 11(8): 4922-34.
[PMID: 31497209]
[6]
Guo Y, Bai M, Lin L, et al. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019.
[7]
Williams M, Cheng YY, Kirschner MB, et al. Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget 2019; 10(41): 4125-38.
[http://dx.doi.org/10.18632/oncotarget.27010] [PMID: 31289611]
[8]
Abdolmaleki F, Ghafoui-Fard S,-F, Taheri M, et al. Expression analysis of a panel of long non-coding RNAs (lncRNAs) revealed their potential as diagnostic biomarkers in bladder cancer. Genomics 2020; 112: 677-82.
[9]
Xu B, Gong X, Zi L, et al. Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA. Can Sci 2019; 455(110): 1676-85.
[10]
Xie ZZ, Xiao ZC, Song YX, Li W, Tan GJ. Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway. Eur Rev Med Pharmacol Sci 2018; 22: 1963-70.
[11]
Chen Z, Zhang J, Zhang Z, et al. death, disease, The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis 2017; 8.
[12]
Chu J, Zhu Y, Sun L, et al. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. 2015; 6: 31944-57.
[13]
Leng J, Song Q, Zhao Y, Wang Z. miR‑15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‑2 expression in human osteosarcoma cells. Int J Oncol 2018; 52(4): 1095-104.
[http://dx.doi.org/10.3892/ijo.2018.4285] [PMID: 29484432]
[14]
Wu D-M, Wen X, Han XR, et al. Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia. Mol Cell Biol 2018; 38(20): 38.
[http://dx.doi.org/10.1128/MCB.00259-18] [PMID: 30037980]
[15]
Veronese A, Pepe F, Chiacchia J, et al. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 2015; 29(1): 86-95.
[http://dx.doi.org/10.1038/leu.2014.139] [PMID: 24732594]
[16]
Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17(1): 28-40.
[http://dx.doi.org/10.1016/j.ccr.2009.11.019] [PMID: 20060366]
[17]
Dal Bo M, Rossi FM, Rossi D, et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2011; 50(8): 633-43.
[http://dx.doi.org/10.1002/gcc.20885] [PMID: 21563234]
[18]
Tagawa H, Ikeda S, Sawada K. Role of microRNA in the pathogenesis of malignant lymphoma. Cancer Sci 2013; 104(7): 801-9.
[http://dx.doi.org/10.1111/cas.12160] [PMID: 23551855]
[19]
Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011; 25(3): 489-97.
[http://dx.doi.org/10.1038/leu.2010.288] [PMID: 21151023]
[20]
Kasar S, Underbayev C, Yuan Y, et al. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene 2014; 33(25): 3307-15.
[http://dx.doi.org/10.1038/onc.2013.291] [PMID: 23995789]
[21]
Zhang X, Chen X, Lin J, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012; 31(24): 3002-8.
[http://dx.doi.org/10.1038/onc.2011.470] [PMID: 22002311]
[22]
Garding A, Bhattacharya N, Claus R, et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB 2013 Genetics. 2013.
[23]
Mian M, Scandurra M, Chigrinova E, et al. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Ann Oncol 2012; 23(3): 729-35.
[http://dx.doi.org/10.1093/annonc/mdr289] [PMID: 21693768]
[24]
Lia M, Carette A, Tang H, et al. Blood, Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. 2012; 119: 2981-90.
[25]
Morenos L, Chatterton Z, Ng JL, et al. Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer 2014; 13: 123.
[http://dx.doi.org/10.1186/1476-4598-13-123] [PMID: 24885794]
[26]
Chen R, Zheng RS, Zhang SW, et al. Analysis of incidence and mortality of esophageal cancer in China, 2015. Zhonghua Yu Fang Yi Xue Za Zhi 2019; 53(11): 1094-7.
[PMID: 31683393]
[27]
Ma W, Zhang CQ, Dang CX, et al. Upregulated long-non-coding RNA DLEU2 exon 9 expression was an independent indicator of unfavorable overall survival in patients with esophageal adenocarcinoma. Biomed Pharmacother 2019; 113: 108655.
[http://dx.doi.org/10.1016/j.biopha.2019.108655] [PMID: 30849637]
[28]
Lei Y, Shi Y, Duan J, et al. Identification of alternative splicing and lncRNA genes in pathogenesis of small cell lung cancer based on their RNA sequencing. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2019; 28: 1043-50.
[29]
Wu W, Zhao Y, Gao E, et al. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p. J Cell Mol Med 2020; 24(1): 441-50.
[http://dx.doi.org/10.1111/jcmm.14749] [PMID: 31721438]
[30]
Chen CQ, Chen CS, Chen JJ, et al. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol Cell Biochem 2013; 383(1-2): 137-48.
[http://dx.doi.org/10.1007/s11010-013-1762-z] [PMID: 23867991]
[31]
Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncol 2014; 16(7): 896-913.
[http://dx.doi.org/10.1093/neuonc/nou087] [PMID: 24842956]
[32]
Banerjee S, Saluja A. Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology : official journal of the International Association of Pancreatology (IAP) 2015; 15: 39-43.
[33]
Cavallari I, Urso L, Sharova E, Pasello G, Ciminale V. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Front Oncol 2019; 9: 740.
[http://dx.doi.org/10.3389/fonc.2019.00740] [PMID: 31475103]
[34]
Lerner M, Harada M, Lovén J, et al. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 2009; 315(17): 2941-52.
[http://dx.doi.org/10.1016/j.yexcr.2009.07.001] [PMID: 19591824]
[35]
Farling KB. Bladder cancer: Risk factors, diagnosis, and management. Nurse Pract 2017; 42(3): 26-33.
[http://dx.doi.org/10.1097/01.NPR.0000512251.61454.5c] [PMID: 28169964]
[36]
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9694-705.
[http://dx.doi.org/10.3748/wjg.v22.i44.9694] [PMID: 27956793]
[37]
Giulietti M, Righetti A, Principato G, Piva F. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer. Carcinogenesis 2018; 39: 1016-25.
[38]
Cossu AM, Mosca L, Zappavigna S, et al. Long Non-coding RNAs as Important Biomarkers in Laryngeal Cancer and Other Head and Neck Tumours. Int J Mol Sci 2019; 20(14): 20.
[http://dx.doi.org/10.3390/ijms20143444] [PMID: 31336999]
[39]
Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet 2018; 14(9): e1007679.
[http://dx.doi.org/10.1371/journal.pgen.1007679] [PMID: 30256787]
[40]
Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat 2016; 159(3): 395-406.
[http://dx.doi.org/10.1007/s10549-016-3947-0] [PMID: 27562585]
[41]
Vendrell JA, Magnino F, Danis E, et al. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 2004; 32(2): 397-414.
[http://dx.doi.org/10.1677/jme.0.0320397] [PMID: 15072547]
[42]
Elnenaei MO, Hamoudi RA, Swansbury J, et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 2003; 36(1): 99-106.
[http://dx.doi.org/10.1002/gcc.10140] [PMID: 12461754]
[43]
Tang D, Yao R, Zhao D, et al. Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy. Sci Rep 2018; 8(1): 3917.
[http://dx.doi.org/10.1038/s41598-018-22257-1] [PMID: 29500455]
[44]
Liu XY, Ma D, Xu XE, et al. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer. Theranostics 2018; 8(22): 6386-99.
[http://dx.doi.org/10.7150/thno.29164] [PMID: 30613307]

Rights & Permissions Print Cite
Article Metrics
33
1
© 2024 Bentham Science Publishers | Privacy Policy